WELWYN GARDEN CITY, England and BOSTON, June 6, 2013 /PRNewswire/ --
Heptares Therapeutics, the leading GPCR drug discovery company, notes that it will be presenting at the following biotech industry events over the coming weeks.
EPIC European Partnering and Investment Conference (London, UK, 6 June)
Dr Barry Kenny, Heptares' Chief Business Officer, will present an overview of the Company at 4:00pm (BST).
Boston Biotech CEO Conference (Boston, MA, USA, 11-12 June)
Mr Dan Grau, Heptares' President, will participate in a panel discussion entitled Building Technology Value: A Checklist of Essentials, at 10:30am (EDT) on 12 June.
For a full list of events at which Heptares will be present, please visit http://www.heptares.com
About Heptares Therapeutics
Heptares creates new medicines targeting clinically important, yet historically challenging, GPCRs (G protein-coupled receptors), a superfamily of drug receptors linked to a wide range of human diseases. Leveraging our advanced structure-based drug design technology platform, we have built an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including Alzheimer's disease, Parkinson's disease, schizophrenia, migraine and diabetes. Our pharmaceutical partners include Shire, Cubist, Takeda, MorphoSys, AstraZeneca and MedImmune, and we are backed by MVM Life Science Partners, Clarus Ventures, Novartis Venture Fund and Takeda Ventures. To learn more about Heptares, please visit http://www.heptares.com.
SOURCE Heptares Therapeutics